| P/E (FY) | 11.3 | Sales (TTM) | $1.10B |
| Earnings (TTM) | $375.6M | ROE | 39.89% |
| Net Margin | 36.49% | ROIC | 14.33% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 27.48% |
ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare disease in North America. It markets NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE for symptoms of Rett syndrome. Its pipeline includes remlifanserin, ACP-211, ACP-711, and other candidates across psychiatric and neurological indications.
| Market Cap | $4.45B | Trading Days | 5293 |
| 52W High | 28.34 |
| 52W Low | 19.69 |
| % Off High | −8.24% |
| YTD | −2.62% | 1Y | 14.99% |
| 3Y | −10.43% | 5Y | 17.43% |
| 10Y | −29.21% | Since incept. (ann.) | 5.17% |
Reportable Segment Aggregation Before Other Operating 100%
| Ann. Volatility (1Y) | 37.12% | Ann. Volatility (3Y) | 49.61% |
| Sharpe (1Y) | 0.57 | Sharpe (3Y) | 0.17 |
| Max Drawdown (1Y) | −27.58% | Max Drawdown (3Y) | −55.62% |
| Beta (3Y, vs SPY) | 1.06 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | $4.34B | — |
| MANE | Veradermics, Inc | $4.66B | — |
| INDV | Indivior Pharmaceuticals, Inc. | $5.00B | 25.0 |
| VKTX | Viking Therapeutics, Inc. | $3.93B | — |
| TNGX | Tango Therapeutics, Inc. | $3.85B | — |
| CPRX | CATALYST PHARMACEUTICALS, INC. | $3.85B | 18.7 |
| TVTX | Travere Therapeutics, Inc. | $5.20B | — |
| AMRN | AMARIN CORP PLC\UK | $5.31B | — |
| DYN | Dyne Therapeutics, Inc. | $3.70B | — |
| ORKA | Oruka Therapeutics, Inc. | $5.46B | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ |
| $5.55B |
| — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.55B | — |
